Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas

Journal of Neuro-Oncology

Volumn 105, Issue 3, 2011, Pages 607-612

  Iwamoto, Fabio M ^a,b   Hottinger, Andreas F ^a,c   Karimi, Sasan ^a   Riedel, Elyn ^a   Dantis, Jocelynn ^a   Jahdi, Maryam ^a   Panageas, Katherine S ^a   Lassman, Andrew B ^a   Abrey, Lauren E ^a   Fleisher, Martin ^a   Deangelis, Lisa M ^a   Holland, Eric C ^a   Hormigo, Adília ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Glioblastoma; Glioma; Matrix metalloproteinase 9; Serum marker

Indexed keywords

GELATINASE B; TEMOZOLOMIDE; TUMOR MARKER;

ADULT; CANCER GRADING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; ENZYME BLOOD LEVEL; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL TIME;

ADULT; BRAIN NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MATRIX METALLOPROTEINASE 9; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 82955203351     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0628-z     Document Type: Conference Paper

References (27)

1. MJ van den Bent MA Vogelbaum PY Wen DR Macdonald SM Chang 2009 End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria J Clin Oncol 27 2905 2908 10.1200/JCO.2009.22.4998 19451418 10.1200/JCO.2009.22.4998
2. G Cairncross B Berkey E Shaw R Jenkins B Scheithauer D Brachman J Buckner K Fink L Souhami N Laperierre M Mehta W Curran 2006 Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 J Clin Oncol 24 2707 2714 10.1200/JCO.2005.04.3414 16782910 10.1200/JCO.2005.04.3414 1:CAS:528:DC%2BD28XntV2hurg%3D (Pubitemid 46630566)
3. MJ van den Bent AF Carpentier AA Brandes M Sanson MJ Taphoorn HJ Bernsen M Frenay CC Tijssen W Grisold L Sipos H Haaxma-Reiche JM Kros MC van Kouwenhoven CJ Vecht A Allgeier D Lacombe T Gorlia 2006 Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial J Clin Oncol 24 2715 2722 10.1200/JCO.2005.04.6078 16782911 10.1200/JCO.2005.04.6078 (Pubitemid 46630567)
4. ME Hegi AC Diserens T Gorlia MF Hamou N de Tribolet M Weller JM Kros JA Hainfellner W Mason L Mariani JE Bromberg P Hau RO Mirimanoff JG Cairncross RC Janzer R Stupp 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 997 1003 10.1056/NEJMoa043331 15758010 10.1056/NEJMoa043331 1:CAS:528:DC%2BD2MXit1Wktro%3D (Pubitemid 40349502)
5. SS Lakka M Rajan C Gondi N Yanamandra N Chandrasekar SL Jasti Y Adachi K Siddique M Gujrati W Olivero DH Dinh G Kouraklis AP Kyritsis JS Rao 2002 Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion Oncogene 21 8011 8019 10.1038/sj.onc.1205894 12439751 10.1038/sj.onc.1205894 1:CAS:528:DC%2BD38XoslGlsL0%3D (Pubitemid 35434187)
6. JS Rao M Yamamoto S Mohaman ZL Gokaslan GN Fuller WG Stetler-Stevenson VH Rao LA Liotta GL Nicolson RE Sawaya 1996 Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas Clin Exp Metastasis 14 12 18 8521611 10.1007/BF00157681 1:STN:280:DyaK287gs1CgtQ%3D%3D (Pubitemid 26009751)
7. G Bergers R Brekken G McMahon TH Vu T Itoh K Tamaki K Tanzawa P Thorpe S Itohara Z Werb D Hanahan 2000 Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis Nat Cell Biol 2 737 744 10.1038/35036374 11025665 10.1038/35036374 1:CAS:528:DC%2BD3cXnsVyntLk%3D
8. A Hormigo B Gu S Karimi E Riedel KS Panageas MA Edgar MK Tanwar JS Rao M Fleisher LM DeAngelis EC Holland 2006 YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas Clin Cancer Res 12 5698 5704 10.1158/1078-0432.CCR-06-0181 17020973 10.1158/1078-0432.CCR-06- 0181 1:CAS:528:DC%2BD28XhtVartbrE (Pubitemid 44629598)
9. JL Clarke FM Iwamoto J Sul K Panageas AB Lassman LM DeAngelis A Hormigo CP Nolan I Gavrilovic S Karimi LE Abrey 2009 Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma J Clin Oncol 27 3861 3867 10.1200/JCO.2008.20.7944 19506159 10.1200/JCO.2008.20.7944 1:CAS:528:DC%2BD1MXhtFaitrrJ
10. DR Macdonald TL Cascino SC Schold Jr JG Cairncross 1990 Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1277 1280 2358840 1:STN:280:DyaK3c3ptlyitQ%3D%3D (Pubitemid 20195640)
11. SL Zeger KY Liang 1992 An overview of methods for the analysis of longitudinal data Stat Med 11 1825 1839 1480876 10.1002/sim.4780111406 1:STN:280:DyaK3s7is1OhtA%3D%3D (Pubitemid 23015633)
12. Cox D, Oakes D (1990) Analysis of survival data. Chapman & Hill, New York
13. K Komatsu Y Nakanishi N Nemoto T Hori T Sawada M Kobayashi 2004 Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas Brain Tumor Pathol 21 105 112 15696970 10.1007/BF02482184 1:CAS:528:DC%2BD2MXhtlSjsLzP (Pubitemid 40187984)
14. MG Tutton ML George SA Eccles S Burton RI Swift AM Abulafi 2003 Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients Int J Cancer 107 541 550 10.1002/ijc.11436 14520690 10.1002/ijc.11436 1:CAS:528:DC%2BD3sXoslequ7s%3D (Pubitemid 37296113)
15. SM Ranuncolo E Matos D Loria M Vilensky R Rojo E Bal de Kier Joffe L Ines Puricelli 2002 Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma Cancer 94 1483 1491 10.1002/cncr.10356 11920505 10.1002/cncr.10356 1:CAS:528:DC%2BD38XisVWmtLs%3D (Pubitemid 34212642)
16. S Zucker J Cao 2005 Measurement of matrix metalloproteinases in serum of patients with melanoma: snarled in technical pitfalls Clin Cancer Res 11 5069 5070 10.1158/1078-0432.CCR-05-0774 16033818 10.1158/1078-0432.CCR-05-0774 1:CAS:528:DC%2BD2MXmt12qtLw%3D (Pubitemid 41003688)
17. J Nikkola P Vihinen MS Vuoristo P Kellokumpu-Lehtinen VM Kahari S Pyrhonen 2005 High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma Clin Cancer Res 11 5158 5166 10.1158/1078-0432.CCR-04-2478 16033831 10.1158/1078-0432.CCR-04-2478 1:CAS:528:DC%2BD2MXmt12qtbs%3D (Pubitemid 41003701)
18. SM Ranuncolo E Armanasco C Cresta E Bal De Kier Joffe L Puricelli 2003 Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients Int J Cancer 106 745 751 10.1002/ijc.11288 12866035 10.1002/ijc.11288 1:CAS:528:DC%2BD3sXms1Wjsrw%3D (Pubitemid 36993399)
19. R Roy J Yang MA Moses 2009 Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer J Clin Oncol 27 5287 5297 10.1200/JCO.2009.23.5556 19738110 10.1200/JCO.2009.23.5556 1:CAS:528: DC%2BD1MXhsFahsLnP
20. ER Smith D Zurakowski A Saad RM Scott MA Moses 2008 Urinary biomarkers predict brain tumor presence and response to therapy Clin Cancer Res 14 2378 2386 10.1158/1078-0432.CCR-07-1253 18413828 10.1158/1078-0432.CCR-07-1253 1:CAS:528:DC%2BD1cXkvFGmtbw%3D (Pubitemid 351551071)
21. G Choe JK Park L Jouben-Steele TJ Kremen LM Liau HV Vinters TF Cloughesy PS Mischel 2002 Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype Clin Cancer Res 8 2894 2901 12231534 1:CAS:528:DC%2BD38XnvVWisbc%3D (Pubitemid 35025737)
22. RF Gerlach JA Uzuelli CD Souza-Tarla JE Tanus-Santos 2005 Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities Anal Biochem 344 147 149 10.1016/j.ab.2005.04.038 15950912 10.1016/j.ab.2005.04.038 1:CAS:528:DC%2BD2MXos1amt7k%3D (Pubitemid 41569391)
23. K Jung M Lein C Laube R Lichtinghagen 2001 Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood Clin Chim Acta 314 241 244 11718702 10.1016/S0009-8981(01)00679-9 1:CAS:528:DC%2BD3MXosFKktrg%3D (Pubitemid 33079205)
24. CD Souza-Tarla JA Uzuelli AA Machado RF Gerlach JE Tanus-Santos 2005 Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities Clin Biochem 38 410 414 10.1016/j.clinbiochem.2005.02.010 15820769 10.1016/j.clinbiochem.2005.02.010 1:CAS:528:DC%2BD2MXjtV2jtbs%3D
25. D Rouy I Ernens C Jeanty DR Wagner 2005 Plasma storage at -80 degrees C does not protect matrix metalloproteinase-9 from degradation Anal Biochem 338 294 298 10.1016/j.ab.2004.10.052 15745750 10.1016/j.ab.2004.10.052 1:CAS:528:DC%2BD2MXitVaqurs%3D (Pubitemid 40312594)
26. MH Friedberg MJ Glantz MS Klempner BF Cole G Perides 1998 Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis Cancer 82 923 930 9486583 10.1002/(SICI)1097-0142(19980301)82: 5<923::AID-CNCR18>3.0.CO;2-2 1:CAS:528:DyaK1cXhsVCru7s%3D (Pubitemid 28104173)
27. MD Groves VK Puduvalli KR Hess KA Jaeckle P Peterson WK Yung VA Levin 2002 Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme J Clin Oncol 20 1383 1388 11870183 10.1200/JCO.20.5.1383 1:CAS:528:DC%2BD38XisVWmu7g%3D (Pubitemid 34177446)